Publications 2021 – cnrmyrma.fr

Cliquer ici pour toutes les publications du CNR-MyRMA en 2021

%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-7dc016dbb075c3ec3ff9354bed174bd8%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22WSG27KUJ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonnet%20et%20al.%22%2C%22parsedDate%22%3A%222021-10-29%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%26%23x201C%3BA%20Comprehensive%20Evaluation%20of%20GeneLEAD%20VIII%20DNA%20Platform%20Combined%20to%20Deeplex%20Myc-TB%26%23xAE%3B%20Assay%20to%20Detect%20in%208%20Days%20Drug%20Resistance%20to%2013%20Antituberculous%20Drugs%20and%20Transmission%20of%20Mycobacterium%20Tuberculosis%20Complex%20Directly%20From%20Clinical%20Samples%26%23x201D%3B%20by%20Isabelle%20Bonnet%20et%20al.%20%3Ci%3EFrontiers%20in%20Cellular%20and%20Infection%20Microbiology%3C%5C%2Fi%3E.%2011%20%28October%2029%2C%202021%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcimb.2021.707244%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcimb.2021.707244%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Comprehensive%20Evaluation%20of%20GeneLEAD%20VIII%20DNA%20Platform%20Combined%20to%20Deeplex%20Myc-TB%5Cu00ae%20Assay%20to%20Detect%20in%208%20Days%20Drug%20Resistance%20to%2013%20Antituberculous%20Drugs%20and%20Transmission%20of%20Mycobacterium%20tuberculosis%20Complex%20Directly%20From%20Clinical%20Samples%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Enouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vichita%22%2C%22lastName%22%3A%22Ok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Jaffr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22The%20GeneLEAD%20VIII%20%28Diagenode%2C%20Belgium%29%20is%20a%20new%2C%20fully%20automated%2C%20sample-to-result%20precision%20instrument%20for%20the%20extraction%20of%20DNA%20and%20PCR%20detection%20of%20Mycobacterium%20tuberculosis%20complex%20%28MTBC%29%20directly%20from%20clinical%20samples.%20The%20Deeplex%20Myc-TB%5Cu00ae%20assay%20%28Genoscreen%2C%20France%29%20is%20a%20diagnostic%20kit%20based%20on%20the%20deep%20sequencing%20of%20a%2024-plexed%20amplicon%20mix%20allowing%20simultaneously%20the%20detection%20of%20resistance%20to%2013%20antituberculous%20%28antiTB%29%20drugs%20and%20the%20determination%20of%20spoligotype.%20We%20evaluated%20the%20performance%20of%20a%20strategy%20combining%20the%20both%20mentioned%20tools%20to%20detect%20directly%20from%20clinical%20samples%2C%20in%208%20days%2C%20MTBC%20and%20its%20resistance%20to%2013%20antiTB%20drugs%2C%20and%20identify%20potential%20transmission%20of%20strains%20from%20patient-to-patient.%20Using%20this%20approach%2C%20we%20screened%20112%20clinical%20samples%20%2865%20smear-negative%29%20and%2094%20MTBC%20cultured%20strains.%20The%20sensitivity%20and%20the%20specificity%20of%20the%20GeneLEAD%5C%2FDeeplex%20Myc-TB%20approach%20for%20MTBC%20detection%20were%2079.3%25%20and%20100%25%2C%20respectively.%20One%20hundred%20forty%20successful%20Deeplex%20Myc-TB%20results%20were%20obtained%20for%2046%20clinical%20samples%20and%2094%20strains%2C%20a%20total%20of%2085.4%25%20of%20which%20had%20a%20Deeplex%20Myc-TB%20susceptibility%20and%20resistance%20prediction%20consistent%20with%20phenotypic%20drug%20susceptibility%20testing%20%28DST%29.%20Importantly%2C%20the%20Deeplex%20Myc-TB%20assay%20was%20able%20to%20detect%20100%25%20of%20the%20multidrug-resistant%20%28MDR%29%20MTBC%20tested.%20The%20lowest%20concordance%20rates%20were%20for%20pyrazinamide%2C%20ethambutol%2C%20streptomycin%2C%20and%20ethionamide%20%2884.5%25%2C%2081.5%25%2C%2073%25%2C%20and%2055%25%2C%20respectively%29%20for%20which%20the%20determination%20of%20susceptibility%20or%20resistance%20is%20generally%20difficult%20with%20current%20tools.%20One%20of%20the%20main%20difficulties%20of%20Deeplex%20Myc-TB%20is%20to%20interpret%20the%20non-synonymous%20uncharacterized%20variants%20that%20can%20represent%20up%20to%2030%25%20of%20the%20detected%20single%20nucleotide%20variants.%20We%20observed%20a%20good%20level%20of%20concordance%20between%20Deeplex%20Myc-TB-spoligotyping%20and%20MIRU-VNTR%20despite%20a%20lower%20discriminatory%20power%20for%20spoligotyping.%20The%20median%20time%20to%20obtain%20complete%20results%20from%20clinical%20samples%20was%208%20days%20%28IQR%207%5Cu201313%29%20provided%20a%20high-throughput%20NGS%20sequencing%20platform%20was%20available.%20Our%20results%20highlight%20that%20the%20GeneLEAD%5C%2FDeeplex%20Myc-TB%20approach%20could%20be%20a%20breakthrough%20in%20rapid%20diagnosis%20of%20MDR%20TB%20in%20routine%20practice.%22%2C%22date%22%3A%222021-10-29%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffcimb.2021.707244%22%2C%22ISSN%22%3A%222235-2988%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8586210%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T23%3A11%3A13Z%22%7D%7D%5D%7D

“A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium Tuberculosis Complex Directly From Clinical Samples” by Isabelle Bonnet et al. Frontiers in Cellular and Infection Microbiology. 11 (October 29, 2021). https://doi.org/10.3389/fcimb.2021.707244.